Qiagen Downgraded by Investment Firm Macquarie | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citing increasing competition in the human papillomavirus testing space and possible austerity measures by the US government, investment firm Macquarie downgraded Qiagen's shares and revised revenue and EPS estimates on Wednesday.

Macquarie also lowered the target price on Qiagen's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.